Related Experiment Videos

[Mid-term results in coronary revascularization using the right gastroepiploic artery graft]

N Uchida1, Y Kawaue

  • 1Department of Cardiovascular Surgery, Hiroshima General Hospital, Japan.

[Zasshi] [Journal]. Nihon Kyobu Geka Gakkai
|December 1, 1996
PubMed

Insights

Coronary artery bypass grafting using the right gastroepiploic artery (REGA) shows good early and mid-term results, including high survival and graft patency rates. However, potential issues like flow competition and gastric cancer require consideration.

Area of Science:

  • Cardiovascular Surgery
  • Thoracic Surgery
  • Surgical Oncology

Background:

  • Coronary artery bypass grafting (CABG) is a critical intervention for coronary artery disease.
  • The right gastroepiploic artery (REGA) is an alternative conduit for CABG, offering potential benefits.
  • Evaluating the long-term efficacy and safety of REGA in CABG is essential for clinical practice.

Purpose of the Study:

  • To assess the mid-term postoperative outcomes of CABG utilizing the right gastroepiploic artery (REGA).
  • To analyze mortality, survival rates, graft patency, cardiac events, and abdominal complications associated with REGA-CABG.

Main Methods:

  • A retrospective study of 191 patients undergoing CABG with REGA, with a mean follow-up of 37 months.
  • Evaluation of outcomes including mortality, survival, graft angiography, cardiac event-free rates, and abdominal complications.
  • Analysis of early and mid-term patency rates and graft performance via angiography.

Main Results:

  • Overall survival rates were 94.2% at 1 year, 90.0% at 3 years, and 85.9% at 5 years.
  • Early REGA patency was 98.9%, with a mid-term patency of 96.4%.
  • Flow competition occurred in 24.0% of cases, and long-term abdominal complications included incisional hernia and gastric cancer.

Conclusions:

  • Early and mid-term results of CABG using REGA are favorable, with good survival and graft patency.
  • Potential challenges include flow competition with native coronary arteries and the long-term risk of gastric cancer.
  • REGA is a viable option for CABG, but careful patient selection and monitoring are warranted.

Related Concept Videos